Mucosal and Plasma Metabolomes in New-onset Paediatric Inflammatory Bowel Disease: Correlations with Disease Characteristics and Plasma Inflammation Protein Markers.
Humans
Child
Sphingomyelins
/ metabolism
Sphingosine
/ metabolism
Chromatography, Liquid
Tandem Mass Spectrometry
Inflammatory Bowel Diseases
/ pathology
Colitis, Ulcerative
/ pathology
Inflammation
/ pathology
Metabolome
C-Reactive Protein
/ metabolism
Intestinal Mucosa
/ pathology
Sphingolipids
/ metabolism
Leukocyte L1 Antigen Complex
/ analysis
Lysophospholipids
/ metabolism
Inflammatory bowel disease
metabolome
paediatric
Journal
Journal of Crohn's & colitis
ISSN: 1876-4479
Titre abrégé: J Crohns Colitis
Pays: England
ID NLM: 101318676
Informations de publication
Date de publication:
03 Apr 2023
03 Apr 2023
Historique:
medline:
5
4
2023
pubmed:
12
10
2022
entrez:
11
10
2022
Statut:
ppublish
Résumé
To advance the understanding of inflammatory bowel disease [IBD] pathophysiology, we compared the mucosal and plasma metabolomes between new-onset paediatric IBD patients and symptomatic non-IBD controls, and correlated plasma inflammation markers and disease characteristics with the altered metabolites. Paired colonic and ileal biopsies and plasma from 67 treatment-naïve children with incident Crohn's disease [CD; n = 47], ulcerative colitis [UC; n = 9], and non-IBD controls [n = 11] were analysed using ultra-performance liquid chromatography-mass spectrometry [UPLC-MS/MS]. Inflammatory plasma proteins [n = 92] were assessed. The metabolomes in inflamed mucosal biopsies differed between IBD patients and controls. In CD, mucosal levels of several lysophospholipids [lysophosphatidylcholines, lysophosphatidyletanolamines, lysophosphatidylinositols, and lysophosphatidylserines] were decreased, correlating with various plasma metabolites including amino acid analogues and N-acetylated compounds. In both CD and UC, mucosal sphingolipids, including ceramide [d18:2/24:1, d18:1/24:2], lactosyl-N-palmitoyl-sphingosine [d18:1/16:0], behenoyl sphingomyelin [d18:1/22:0], lignoceroyl sphingomyelin [d18:1/24:0], and/or sphingomyelin [d18:1/24:1, d18:2/24:0] were increased, correlating with sphingolipids, bile acids, and/or N-acetylated metabolites in plasma. Among proteins associated with CD, interleukin-24 correlated with plasma metabolites, including lactosyl-N-palmitoyl sphingosine [d18:1/16:0] and phosphatidyletanolamine [18:1/18:1], haemoglobin, and faecal calprotectin. In UC, interleukin-24, interleukin-17A, and C-C motif chemokine 11 correlated with several plasma metabolites, including N-acetyltryptophan, tryptophan, glycerate, and threonate, and with the Paediatric Ulcerative Colitis Activity Index, C-reactive protein, and faecal calprotectin. Mucosal perturbations of lysophospholipids and sphingolipids characterised the metabolome in new-onset paediatric IBD and correlated with plasma metabolites. By integrating plasma metabolomics data with inflammatory proteins and clinical data, we identified clinical and inflammatory markers associated with metabolomic signatures for IBD.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
To advance the understanding of inflammatory bowel disease [IBD] pathophysiology, we compared the mucosal and plasma metabolomes between new-onset paediatric IBD patients and symptomatic non-IBD controls, and correlated plasma inflammation markers and disease characteristics with the altered metabolites.
METHODS
METHODS
Paired colonic and ileal biopsies and plasma from 67 treatment-naïve children with incident Crohn's disease [CD; n = 47], ulcerative colitis [UC; n = 9], and non-IBD controls [n = 11] were analysed using ultra-performance liquid chromatography-mass spectrometry [UPLC-MS/MS]. Inflammatory plasma proteins [n = 92] were assessed.
RESULTS
RESULTS
The metabolomes in inflamed mucosal biopsies differed between IBD patients and controls. In CD, mucosal levels of several lysophospholipids [lysophosphatidylcholines, lysophosphatidyletanolamines, lysophosphatidylinositols, and lysophosphatidylserines] were decreased, correlating with various plasma metabolites including amino acid analogues and N-acetylated compounds. In both CD and UC, mucosal sphingolipids, including ceramide [d18:2/24:1, d18:1/24:2], lactosyl-N-palmitoyl-sphingosine [d18:1/16:0], behenoyl sphingomyelin [d18:1/22:0], lignoceroyl sphingomyelin [d18:1/24:0], and/or sphingomyelin [d18:1/24:1, d18:2/24:0] were increased, correlating with sphingolipids, bile acids, and/or N-acetylated metabolites in plasma. Among proteins associated with CD, interleukin-24 correlated with plasma metabolites, including lactosyl-N-palmitoyl sphingosine [d18:1/16:0] and phosphatidyletanolamine [18:1/18:1], haemoglobin, and faecal calprotectin. In UC, interleukin-24, interleukin-17A, and C-C motif chemokine 11 correlated with several plasma metabolites, including N-acetyltryptophan, tryptophan, glycerate, and threonate, and with the Paediatric Ulcerative Colitis Activity Index, C-reactive protein, and faecal calprotectin.
CONCLUSIONS
CONCLUSIONS
Mucosal perturbations of lysophospholipids and sphingolipids characterised the metabolome in new-onset paediatric IBD and correlated with plasma metabolites. By integrating plasma metabolomics data with inflammatory proteins and clinical data, we identified clinical and inflammatory markers associated with metabolomic signatures for IBD.
Identifiants
pubmed: 36219554
pii: 6758389
doi: 10.1093/ecco-jcc/jjac149
pmc: PMC10069620
doi:
Substances chimiques
Sphingomyelins
0
Sphingosine
NGZ37HRE42
C-Reactive Protein
9007-41-4
Sphingolipids
0
Leukocyte L1 Antigen Complex
0
Lysophospholipids
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
418-432Subventions
Organisme : Örebro University
ID : OLL-890291
Organisme : Swedish Research Council
ID : 2020-02021
Organisme : Gillbergska Foundation
Organisme : Söderbergs Foundation
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation.
Références
Gastroenterology. 2022 Apr;162(4):1147-1159.e4
pubmed: 34995526
Prog Lipid Res. 2012 Jul;51(3):199-207
pubmed: 22465125
N Engl J Med. 2021 Sep 30;385(14):1280-1291
pubmed: 34587385
PLoS One. 2009 Sep 29;4(9):e7197
pubmed: 19787068
Nucleic Acids Res. 2022 Jan 7;50(D1):D622-D631
pubmed: 34986597
Nature. 2020 Feb;578(7796):527-539
pubmed: 32103191
J Pediatr Gastroenterol Nutr. 1991 May;12(4):439-47
pubmed: 1678008
Gastroenterology. 2007 Aug;133(2):423-32
pubmed: 17681163
Gastroenterology. 2014 May;146(6):1470-6
pubmed: 24631493
Gastroenterology. 2021 Nov;161(5):1526-1539.e9
pubmed: 34298022
Metabolites. 2019 Nov 27;9(12):
pubmed: 31783598
BMC Gastroenterol. 2017 Jan 31;17(1):23
pubmed: 28143594
J Clin Med. 2021 Feb 06;10(4):
pubmed: 33562024
Nat Rev Gastroenterol Hepatol. 2014 Jan;11(1):55-67
pubmed: 23982684
J Lipid Res. 2007 Dec;48(12):2664-72
pubmed: 17720959
Clin Gastroenterol Hepatol. 2013 Jan;11(1):49-54.e1
pubmed: 22902762
Magn Reson Imaging. 2009 Jan;27(1):79-86
pubmed: 18599242
Nat Rev Gastroenterol Hepatol. 2020 Apr;17(4):223-237
pubmed: 32076145
BioData Min. 2012 Nov 13;5(1):19
pubmed: 23148523
J Crohns Colitis. 2021 May 4;15(5):813-826
pubmed: 33175138
Biochim Biophys Acta Mol Cell Biol Lipids. 2021 Feb;1866(2):158854
pubmed: 33157277
Gastrointest Endosc. 2004 Oct;60(4):505-12
pubmed: 15472670
Inflamm Bowel Dis. 2009 Nov;15(11):1705-20
pubmed: 19504612
Adv Med Sci. 2020 Mar;65(1):65-70
pubmed: 31901795
Biomolecules. 2020 Jul 21;10(7):
pubmed: 32708181
Bioinformatics. 2019 Sep 1;35(17):3055-3062
pubmed: 30657866
J Crohns Colitis. 2017 Mar 01;11(3):321-334
pubmed: 27609529
Inflamm Bowel Dis. 2009 Aug;15(8):1218-23
pubmed: 19161178
Inflamm Bowel Dis. 2011 Jan;17(1):112-7
pubmed: 20812330
PLoS One. 2017 Oct 5;12(10):e0186142
pubmed: 28982144
Nature. 2019 May;569(7758):655-662
pubmed: 31142855
Metabolomics. 2018 Jan;14(1):17
pubmed: 29681789
Inflamm Bowel Dis. 2011 Jun;17(6):1314-21
pubmed: 21560194
Sci Rep. 2020 Nov 3;10(1):18879
pubmed: 33144591
Microorganisms. 2022 Jul 07;10(7):
pubmed: 35889090
Digestion. 1991;50(3-4):135-41
pubmed: 1812040
Nucleic Acids Res. 2021 Jul 2;49(W1):W388-W396
pubmed: 34019663
Biostatistics. 2014 Jul;15(3):569-83
pubmed: 24550197
Gut. 1994 Nov;35(11):1593-8
pubmed: 7828979
J Clin Med. 2019 Jul 04;8(7):
pubmed: 31277430
Microbiome. 2019 May 15;7(1):75
pubmed: 31092280
SLAS Technol. 2021 Apr;26(2):165-177
pubmed: 33207993
Biochim Biophys Acta Mol Cell Biol Lipids. 2018 Dec;1863(12):1458-1468
pubmed: 30251703
J Transl Med. 2021 Jun 2;19(1):237
pubmed: 34078403
J Immunol. 2016 Aug 15;197(4):1425-34
pubmed: 27402702
Int J Biol Sci. 2022 Feb 14;18(5):1813-1828
pubmed: 35342362
Mediators Inflamm. 2015;2015:964131
pubmed: 25948887
Sci Signal. 2021 Sep 28;14(702):eabf6584
pubmed: 34582249
Inflamm Bowel Dis. 2019 Jun 18;25(7):1120-1128
pubmed: 30772902
BMC Med. 2017 Oct 16;15(1):184
pubmed: 29032767
Gastroenterology. 2017 Dec;153(6):1504-1516.e2
pubmed: 28827067
Adv Drug Deliv Rev. 2020;159:133-169
pubmed: 32628989
J Pediatr Gastroenterol Nutr. 2014 Jun;58(6):795-806
pubmed: 24231644
PLoS One. 2013 Oct 18;8(10):e76532
pubmed: 24204637
World J Gastroenterol. 2014 Jan 7;20(1):163-74
pubmed: 24415869
Digestion. 2002;66(1):23-9
pubmed: 12379812
Proteomes. 2020 Aug 10;8(3):
pubmed: 32784952
J Proteome Res. 2012 Jun 1;11(6):3344-57
pubmed: 22574726
Dig Dis Sci. 2012 Aug;57(8):2157-65
pubmed: 22488632
EBioMedicine. 2020 Feb;52:102652
pubmed: 32058942
Nat Rev Gastroenterol Hepatol. 2021 Jan;18(1):56-66
pubmed: 33033392